Epidarex leads €14m series-A for Topas Therapeutics

Listed buyout firm Gimv committed a €4m equity ticket. Topas was carved out from German pharmaceutical company Evotec in a previous round.

As part of the deal, Evotec will retain a controlling stake of Topas, while its CEO, Werner Lanthaler, will be interim chair of Topas's supervisory board.

The capital injected will allow the company to expand and accelerate its proprietary tolerance induction platform and develop its products into a clinical proof-of-concept stage. Initiation of the first clinical trials is expected in 2017, according to a statement.

Company
Based in Hamburg, Topas develops a nanoparticle-based platform to treat autoimmune diseases, allergies and drug-induced immune reaction.

People
Epidarex Capital – Peter Finan (partner).
Evotec – Werner Lanthaler (CEO).
Gimv – Karl Nägler (partner).
Topas – Johannes Herkel (founder); Timm Jessen (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Healthcare
• DACH
• Germany
• Gimv
• Venture